For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
News-Medical.Net on MSN
Peptide-based platform marks a major step toward needle-free diabetes care
For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...
Researchers from Kumamoto University have developed a new peptide-based technology that enables insulin—normally injected—to be taken orally while still powerfully lowering blood sugar. Their ...
For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the ...
Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.
- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, ...
Australians are buying an unapproved weight-loss drug from suppliers whose websites list the product as “for research use ...
US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that may mimic GLP-1 drugs for years after ...
News Medical on MSN
New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders
By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results